FDA approves boxed warning on Invokana label

The labels of the type 2 diabetes drugs Invokana, Invokana and Invokamet XR have been updated to include a new boxed warning regarding an increased risk of leg and foot amputations, the Food and Drug Administration (FDA) announced. The approved safety label update comes two months after the FDA issued a Safety Communication alerting the public that after a review of clinical trial data, the agency has determined that its strongest warning should be added to the labels of all drugs that contain the active ingredient canagliflozin regarding the amputation risk. Invokana, Invokamet and Invokamet XR all contain canagliflozin. The ... Read More